Company / Operating Margin
Neurocrine Biosciences Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
21.6%
FY2025
5-year range
9.0% / 24.2%
FY2021-FY2025
Trend
-10.7%
vs FY2024
Sector context
#24 of 135
Health Care
What the data says
Neurocrine Biosciences's operating margin of 21.6% is higher than 82% of companies in the Health Care sector (FY2025). Operating Margin has fluctuated over the past 9 years, ranging from -982.5% in FY2016 to 24.2% in FY2024.
Based on SEC 10-K filings.
21.6% in FY2025 with a 5-year CAGR of +6.1%. Top quartile in the Health Care sector.
Improved from 13.3% to 21.6% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +6.1pp
- 5-Year Change
- +6.1pp
- 10-Year Change
- -
Sector benchmark
+102.8% above sector average
Key checks
Key Insights
- In FY2025, operating margin decreased 10.7% year-over-year.
- Currently 796.1pp above the Health Care sector average.
- Peak operating margin was recorded in FY2024.
- Lowest operating margin in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 21.6% | -10.7% |
| FY2024 | 24.2% | +82.1% |
| FY2023 | 13.3% | -14.6% |
| FY2022 | 15.6% | +72.3% |
| FY2021 | 9.0% | -42.0% |
| FY2020 | 15.6% | +69.9% |
| FY2019 | 9.2% | +12.4% |
| FY2018 | 8.2% | - |
| FY2017 | - | - |
| FY2016 | -982.5% | -106.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026